Charles Rhyee, an analyst from TD Cowen, maintained the Buy rating on Charles River Labs. The associated price target remains the same with $179.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Charles Rhyee has given his Buy rating due to a combination of factors that suggest potential stability and value creation for Charles River Labs. Despite recent pressures from elevated cancellations in the DSA segment and management’s guidance for a similar B2B ratio in the second half of the year, Rhyee views the stabilization of demand as a positive sign. This stability in demand, particularly in the large pharma and biotech sectors, indicates confidence in maintaining current levels, which supports a favorable outlook.
Moreover, Rhyee highlights the opportunity for significant value creation through the potential sale of the manufacturing segment. Although updates on this strategic review are not expected until the second half of 2025, the prospect of such a sale adds to the long-term attractiveness of the stock. Additionally, while current B2B ratios pose challenges for core revenue growth in 2026, the shorter booking cycles of preclinical CRO studies leave room for potential revenue growth if demand accelerates in the future.
In another report released on August 7, Deutsche Bank also maintained a Buy rating on the stock with a $185.00 price target.